23985-81-1

Basic information

• Product Name: dibenzo[b,d]thiophene-4-carbaldehyde
• Synonyms: dibenzo[b,d]thiophene-4-carbaldehyde;dibenzo[b,d]thiophene-4-carbaldehyde(SALTDATA: FREE);4-Dibenzothiophenecarboxaldehyde;Dibenzo[b,d]thiophene-4-carboxaldehyde, 98%;Dibenzothiophene-4-carboxaldehyde;Dibenzo[b,d]thiophene-4-carbaldehyde AldrichCPR
• CAS NO: 23985-81-1
• Molecular Formula: C₁₃H₈OS
• Molecular Weight: 212.27
• Mol File: 23985-81-1.mol
• Article Data: 7

Chemical Properties

• Melting Point: 125.0 to 129.0 °C
• Boiling Point: 403.6°C at 760 mmHg
• Flash Point: 197.9°C
• Appearance: Pale yellow/Powder
• Density: 1.336±0.06 g/cm3 (20 ºC 760 Torr)
• Vapor Pressure: 1E-06mmHg at 25°C
• Refractive Index: 1.787
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: dibenzo[b,d]thiophene-4-carbaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: dibenzo[b,d]thiophene-4-carbaldehyde(23985-81-1)
• EPA Substance Registry System: dibenzo[b,d]thiophene-4-carbaldehyde(23985-81-1)

Safety Data

• Statements: 22-36/37/38
• Safety Statements: 26-36/37-60
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 23985-81-1(Hazardous Substances Data)

Usage

Uses

dibenzo[b,d]thiophene-4-carbaldehyde is used as a research compound for organic synthesis, etc.

InChI:InChI=1/C13H8OS/c14-8-9-4-3-6-11-10-5-1-2-7-12(10)15-13(9)11/h1-8H

Upstream product

• 7372-88-5 4-methyldibenzothiophene 
• 108847-20-7 4-dibenzothiophene boronic acid 
• 298-12-4 Glyoxilic acid 
• 132-65-0 dibenzothiophene 
• 68-12-2 N,N-dimethyl-formamide 

Downstream Products

• 87643-02-5 4-(o-carboxybenzyl)dibenzothiophene 
• 87643-03-6 4-(2-hydroxymethylbenzyl)dibenzothiophene 

Relevant articles and documents

Systematic structure-activity relationship (SAR) exploration of diarylmethane backbone and discovery of a highly potent novel uric acid transporter 1 (URAT1) inhibitor

In order to systematically explore and better understand the structure-activity relationship (SAR) of a diarylmethane backbone in the design of potent uric acid transporter 1 (URAT1) inhibitors, 33 compounds (1a-1x and 1ha-1hi) were designed and synthesized, and their in vitro URAT1 inhibitory activities (IC50) were determined. The three-round systematic SAR exploration led to the discovery of a highly potent novel URAT1 inhibitor, 1h, which was 200-and 8-fold more potent than parent lesinurad and benzbromarone, respectively (IC50 = 0.035 μM against human URAT1 for 1h vs. 7.18 μM and 0.28 μM for lesinurad and benzbromarone, respectively). Compound 1h is the most potent URAT1 inhibitor discovered in our laboratories so far and also comparable to the most potent ones currently under development in clinical trials. The present study demonstrates that the diarylmethane backbone represents a very promising molecular scaffold for the design of potent URAT1 inhibitors.

Synthesis of Aldehydes by Organocatalytic Formylation Reactions of Boronic Acids with Glyoxylic Acid

Reported herein is a conceptually novel organocatalytic strategy for the formylation of boronic acids. New reactivity is engineered into the α-amino-acid-forming Petasis reaction occurring between aryl boronic acids, amines, and glyoxylic acids to prepare aldehydes. The operational simplicity of the process and its ability to generate structurally diverse and valued aryl, heteroaryl, and α,β-unsaturated aldehydes containing a wide array of functional groups, demonstrates the practical utility of the new synthetic strategy.

Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives

The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions of compounds of Formula (A): wherein Ar, Y, R1 and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder ("ADHD"), enhancing function in disorders associated with hypofunctionality of the cerebral cortex, including, but not limited to, depression, schizophrenia, fatigue, in particular, fatigue associated with neurologic disease, such as multiple sclerosis, chronic fatigue syndrome, and improvement of cognitive dysfunction.